In summary, we have shown that PTM and PTM-loaded liposome nanoparticles could be used to reduce the development of NAFLD in a murine model through modulating DNL via FASN inhibition. The gene discussed is DNASE2; the disease is metabolic dysfunction-associated steatotic liver disease.